How does OK10's PB Ratio compare to its peers?

OK10 has negative equity and a Price-To-Book Ratio (-15.9x) compared to the peer average (4.3x).

How does OK10's PB Ratio compare vs other companies in the DE Biotechs Industry?

OK10 has negative equity and a Price-To-Book Ratio (-15.9x) compared to the European Biotechs industry average (2.5x).

What is OK10's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate OK10's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of OK10 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

OK10 (€1.36) is trading below our estimate of [[fair value]] (€9.4)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

OKYO Pharma (DB:OK10) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

OK10 Stock Overview

A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details

OK10 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 85.5% below our estimate of its fair value

Earnings are forecast to grow 109.75% per year

Risk Analysis

Makes less than USD$1m in revenue (£0)

Negative shareholders equity

Shares are highly illiquid

Does not have a meaningful market cap (€42M)

+ 1 more risk

OKYO Pharma Limited Competitors

4SC

DB:VSC

€50.2m

Medigene

XTRA:MDG1

€17.4m

2invest

XTRA:2INV

€62.7m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Price History & Performance

Summary of all time highs, changes and price drops for OKYO Pharma
Historical stock prices
Current Share Price	US$1.36
52 Week High	US$2.84
52 Week Low	US$1.05
Beta	-2.91
11 Month Change	0%
3 Month Change	-4.23%
1 Year Change	-31.66%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-31.00%

Recent updates

Shareholder Returns

	OK10	DE Biotechs	DE Market
7D	0%	-1.1%	1.1%
1Y	-31.7%	-18.8%	7.2%

Return vs Industry: OK10 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: OK10 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is OK10's price volatile compared to industry and market?
OK10 volatility
OK10 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: OK10 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine OK10's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2007	8	Gary Jacob	okyopharma.com

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.

OKYO Pharma Limited Fundamentals Summary

How do OKYO Pharma's earnings and revenue compare to its market cap?
OK10 fundamental statistics
Market cap	€38.30m
Earnings (TTM)	-€15.54m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.5x

P/E Ratio

Is OK10 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OK10 income statement (TTM)
Revenue	UK£0
Cost of Revenue	UK£6.85m
Gross Profit	-UK£6.85m
Other Expenses	UK£6.42m
Earnings	-UK£13.27m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.52
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-107.9%

How did OK10 perform over the long term?

See historical performance and comparison

This company listing is no longer active

OK10 Stock Overview

Rewards

Risk Analysis

OKYO Pharma Limited Competitors

DB:VSC

€50.2m

XTRA:MDG1

€17.4m

XTRA:2INV

€62.7m

XTRA:HPHA

€105.8m

Price History & Performance

Recent News & Updates

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Recent updates

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

Shareholder Returns

Price Volatility

About the Company

OKYO Pharma Limited Fundamentals Summary

0.0x

-2.5x

Earnings & Revenue